- Home
- BDJ vs SDGR Comparison
BDJ vs SDGR Comparison
Compare BDJ & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDJ | SDGR |
|---|---|---|
| Founded | 2005 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BDJ | SDGR |
|---|---|---|
| Price | $9.70 | $13.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 561.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $256,951,000.00 |
| Revenue This Year | N/A | $23.69 |
| Revenue Next Year | N/A | $20.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.90 |
| 52 Week Low | $6.91 | $12.81 |
| 52 Week High | $8.66 | $28.47 |
Technical Indicators
Market Signals| Indicator | BDJ | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 58.38 | 24.16 |
| Support Level | $9.55 | $12.89 |
| Resistance Level | $9.71 | $14.43 |
| Average True Range (ATR) | 0.08 | 0.75 |
| MACD | -0.00 | -0.29 |
| Stochastic Oscillator | 77.63 | 2.57 |
Price Performance
Historical ComparisonAbout BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.